Scoc as A Drug Target for HGFR2-related Diseases (G60592)

Target Name: SCOC

NCBI ID: G60592

SCOC

Scoc as A Drug Target for HGFR2-related Diseases

SCOC (short for Selective Complement Oxygenase C1), is a enzyme that is involved in the metabolism of a protein called human growth factor receptor 2 (HGFR2). HGFR2 is a protein that is found on the surface of many different types of cells in the body, including cancer cells.

Recent studies have suggested that HGFR2 may be a potential drug target for a variety of diseases, including cancer. Because SCOC is involved in the metabolism of HGFR2, it may be a useful biomarker for tracking the effectiveness of drugs that target this protein.

In addition to its potential as a drug target, HGFR2 has also been shown to be a promising biomarker for cancer. Studies have shown that HGFR2 levels are often elevated in many types of cancer, and that targeting this protein may be an effective way to diagnose and treat these diseases.

One of the challenges in studying HGFR2 as a potential drug target is its complex metabolism. HGFR2 is broken down into its constituent parts by a number of different enzymes, and it is not clear how these enzymes work together to produce the final product. This complexity may make it difficult to develop new drugs that specifically target HGFR2.

However, researchers are still working to understand the metabolism of HGFR2 and to identify potential drug targets. They are also studying the structure of the protein to try to understand how it functions and where it is involved in the body.

While the potential use of SCOC as a drug target is still in its early stages, it is an exciting area of research that could lead to new and effective treatments for a variety of diseases.

Protein Name: Short Coiled-coil Protein

Functions: Positive regulator of amino acid starvation-induced autophagy

The "SCOC Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SCOC comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets